At a glance
| Abbreviation | HuAHV2, HSV2 |
|---|---|
| ICTV species | Simplexvirus humanalpha2 |
| Family | Orthoherpesviridae |
| Baltimore class | I — dsDNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: human alphaherpesvirus 2; herpes simplex virus 2; Simplexvirus humanalpha2
Duplodnaviria › Peploviricota › Herviviricetes › Herpesvirales › Orthoherpesviridae › Simplexvirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Duplodnaviria |
|---|---|
| Kingdom | Heunggongvirae |
| Phylum | Peploviricota |
| Class | Herviviricetes |
| Order | Herpesvirales |
| Family | Orthoherpesviridae |
| Subfamily | Alphaherpesvirinae |
| Genus | Simplexvirus |
| ICTV identifier | ICTV19760237 |
| NCBI taxon | 3050293 |
| Exemplar isolate | JN561323 |
Host evidence
- human: 2,016 GenBank records
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
Not searched yet. Burden, severity and transmissibility figures have not been curated for this virus yet. When they are, each will carry the exact sentence from its source.
Vaccines
Nothing in use found in the sources searched. That is not the same as nothing existing; see the methods page for what was searched.
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| BNT163 | BioNTech SE | Not searched yet | Routine immunisation | Phase 1 | Not searched yet | NCT05432583 | candidateId ctgov-bnt163-biontech-se (targetDisease 'Genital Herpes Si |
| HSV 2 Formulation 1 | Sanofi Pasteur, a Sanofi Company | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT04222985 | candidateId ctgov-hsv-2-formulation-1-sanofi-pasteur-a-sanofi-company |
| Lower dose formulation of HSV vaccine (GSK4108771A) | GlaxoSmithKline | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT04762511 | candidateId ctgov-lower-dose-formulation-of-hsv-vaccine-gsk4108771a-gl |
Antivirals
| Name | Mechanism | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|
| Acyclovir And HydrocortisoneXerese | Non-nucleoside polymerase inhibitor | Treatment | Approved | US: approved | — | quote1 INDICATIONS AND USAGE XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]; SPL id a4efb63c-e7bf-43da-bbfe-463f672cb1bc · verified 2026-10-30 |
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Vaccine pipeline — candidates listed under “Genital Herpes”
- Other Orthoherpesviridae viruses